<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03997617</url>
  </required_header>
  <id_info>
    <org_study_id>PFP-001</org_study_id>
    <nct_id>NCT03997617</nct_id>
  </id_info>
  <brief_title>Personalized Functional Profiling in Metastatic Gastrointestinal Cancer or Recurrent Glioblastoma Patients in Luxembourg.</brief_title>
  <official_title>Pilot Study to Explore the Integrated Personalized Functional Profiling (PFP) for Cancer Patients With Metastatic Gastrointestinal Cancer (mGIC) or Recurrent Glioblastoma (rGBM) in Luxembourg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luxembourg Institute of Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Integrated Biobank of Luxembourg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laboratoire National de Santé (Luxembourg)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier du Luxembourg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hopitaux Robert Schuman (Luxembourg)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Luxembourg Institute of Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are developing a novel standardized and centralized approach named
      Integrated Personalized Functional Profiling (PFP) in Luxembourg. Based on recent
      improvements in cancer biopsy-derived 3D-culture technologies the PFP process will screen
      patient derived cells (PDCs) with FDA/EMA-approved drugs to generate personalized functional
      response profiles. The selected drug through PFP technology will provide personalized
      treatment recommendation for the patient.

      This pilot study will evaluate the clinical feasibility of setting-up an effective workflow
      as a first step. Outcomes from this study will be used subsequently to help plan the clinical
      validation of the implementation of PFP.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2019</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients for which a treatment recommendation for their specific cancer can be formulated, based on PFP</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantity of cells needed for the PFP analysis</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of the PFP process for one specific patient</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of drugs recommended by using the PFP approach</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients for which the treatment recommendation issued by PFP were followed by the investigator</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Oncology</condition>
  <arm_group>
    <arm_group_label>Personalized Functional Profiling</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Personalized Functional Profiling</intervention_name>
    <description>During this pilot study, the overall goal of the project is to establish an effective workflow between the patient, the PFP platform, the clinician and return to the patient. This includes collection of the biopsy or surgery piece and standardized processing, dissociation, drug profiling and issuing treatment recommendation to the clinician. In case the clinician follows this treatment recommendation, patient management and follow up will be performed according to standard of care.</description>
    <arm_group_label>Personalized Functional Profiling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with recurrent Glioblastoma (rGBM) or with metastatic gastrointestinal cancer
             (mGIC), i.e. adenocarcinoma (any grade) of stomach, liver, pancreas, small intestine,
             colon, rectum

          -  The patient has received previous cancer treatment for mGIC or rGBM

          -  Male or female ≥ 18 years

          -  Life expectancy ≥ 12 weeks

          -  Histologically or cytologically confirmed diagnosis for mGIC or recurrence of a
             glioblastoma, WHO grade IV

          -  For women of childbearing potential, a negative pregnancy test documented prior to the
             screening visit is required

          -  Signed Inform Consent Form before any study related procedure

        Exclusion Criteria:

          -  For female patient, being pregnant, planning a pregnancy or breastfeeding

          -  No fresh and viable tumor material available

          -  Known active Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis
             C Virus (HCV) infection

          -  Uncontrolled medical conditions (i.e, diabetes mellitus, hypertension, etc),
             psychological, familial, sociological, or geographical conditions that do not allow
             compliance with the protocol; or unwillingness or inability to follow the procedures
             required in the protocol

          -  In mGIC arm, patient with non-adenocarcinoma gastrointestinal cancer

          -  Patient unable to understand and consent himself
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Guy Berchem, MD</last_name>
    <phone>+35244112084</phone>
    <email>berchem.guy@chl.lu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manon Gantenbein, PhD</last_name>
    <phone>+35226970807</phone>
    <email>manon.gantenbein@lih.lu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre hospitalier de Luxembourg</name>
      <address>
        <city>Luxembourg</city>
        <zip>1210</zip>
        <country>Luxembourg</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy Berchem, MD</last_name>
      <phone>+35244112084</phone>
      <email>berchem.guy@chl.lu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Robert Schmuan</name>
      <address>
        <city>Luxembourg</city>
        <zip>2540</zip>
        <country>Luxembourg</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Berna, MD</last_name>
      <phone>+352 (28) 88 6550</phone>
      <email>marc.berna@hopitauxschuman.lu</email>
    </contact>
  </location>
  <location_countries>
    <country>Luxembourg</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>June 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2019</study_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

